GHRP-6: Benefits, Dosage & FDA Status
Growth Hormone Releasing Peptide 6
An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.
FDA Status
Not FDA-approved — research compound
Typical Dose
100–300 mcg, 1–3 times daily (subcutaneous)
Evidence Grade
BLimited clinical + robust preclinical evidence
Half-Life
~15–30 minutes
Routes of Administration
subcutaneous
First Synthesized
1980s
Clinics Indexed
64 providers have offered GHRP-6 in our tracked directory.
Mechanism of Action
Hexapeptide GHS-R1a agonist with notably strong ghrelin-mimetic appetite stimulation.
Key Reported Benefits
- ✓GH release
- ✓Appetite stimulation
- ✓Cytoprotection
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.
Reported Side Effects
- •Hunger surge
- •Water retention
- •Cortisol elevation
Contraindications
- ⚠Active malignancy
- ⚠Pregnancy
Commonly Stacked With
Regulatory & Safety Context
FDA status: Not FDA-approved — research compound
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on GHRP-6. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
CJC-1295 (no DAC)
BA growth hormone releasing hormone (GHRH) analog most commonly stacked with Ipamorelin to stimulate natural GH pulsatile release without disrupting the hypothalamic axis.
Ipamorelin
BA selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.
Tesamorelin
AAn FDA-approved GHRH analog that stimulates natural growth hormone production. Clinically proven to reduce visceral adipose tissue and increasingly used off-label for body recomposition.
Sermorelin
B+The original synthetic GHRH(1–29) and the most accessible GH-stimulating peptide for age-related hormone decline. Stimulates the body's own pulsatile GH release rather than replacing it.
MK-677
B+An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
GHRP-2
BA potent synthetic ghrelin-mimetic GH secretagogue. Drives strong GH spikes but raises cortisol and prolactin more than newer alternatives like Ipamorelin.